Tarsus Pharmaceuticals, Inc.
For the period ended Dec 31, 2025. Filed Feb 23, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 23, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
Securities Trading Plans of Directors and Executive Officers
As previously disclosed, in December 2024, Bobak Azamian, our Chief Executive Officer adopted a Rule 10b5-1 trading plan to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. The plan provided for the sale of up to 24,000 shares of common stock held by Dr. Azamian between March 24, 2025, and March 23, 2026. During the year ended December 31, 2025, Dr. Azamian sold all 24,000 shares under this plan and it was subsequently terminated. In December 2025, Dr. Azamian, adopted a new Rule 10b5-1 trading plan. The plan provides for the sale of up to 60,000 shares of common stock held by Dr. Azamian between March 24, 2026 and March 24, 2027.
On November 13, 2025, Seshadri Neervannan, our Chief Operating Officer, adopted a Rule 10b5-1 trading plan to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. The plan provides for the sale of up to 18,027 shares of common stock held by Dr. Neervannan between March 4, 2026 and March 16, 2026.
In September 2025, Dianne Whitfield, our Chief Human Resources Officer, adopted a Rule 10b5-1 trading plan to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. The plan provided for the sale of up to 57,925 shares of common stock held by Ms. Whitfield between December 16, 2025 and April 1, 2026. For the year ended December 31, 2025, Ms. Whitfield sold 7,397 shares pursuant to this Rule 10b5-1 trading plan. In January 2026, Ms. Whitfield sold an additional 15,565 shares under the plan. On January 20, 2026, Ms. Whitfield cancelled the Rule 10b5-1 trading plan, at which time 34,963 shares remained unsold under this plan.
In September 2025, William Link, a member of our Board of Directors, adopted a Rule 10b5-1 trading plan to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act. The plan provides for the sale of up to 50,000 shares of common stock held by Dr. Link between December 15, 2025 and December 14, 2026. For the year ended December 31, 2025, Dr. Link sold 12,500 shares under this plan.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.